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Since 5-HT6 receptors play role in controlling feeding and satiety and dopamine is
essential for normal feeding behavior, we evaluated the ability of EMD 386088—5-HT6
receptor partial agonist and dopamine transporter inhibitor—to reduce body weight in
obese rats, as well as its anorectic properties (calorie intake reduction) in rat model of
excessive eating and the influence on metabolism (plasma glucose and glycerol levels).
We also determined the effect of the studied compound on pica behavior in rats and
its influence on blood pressure after single administration. EMD 386088 reduced body
weight in obese rats fed high-fat diet and decreased calorie intake in both models
applied (rat model of obesity and of excessive eating). In both models EMD 386088
regulated plasma glucose and increased plasma glycerol levels. The latter proves that
the compound reduced body fat. We think that it might have increased lipolysis, but this
requires further studies. The reduction in glucose levels is the first symptom of metabolic
disorders compensation. EMD 386088 did not cause pica behavior in rats but increased
blood pressure after single administration. We think that partial 5-HT6 agonists might
have potential in the treatment of obesity. Thus, EMD 386088 requires extended studies.
Keywords: EMD386088, 5-HT6 receptor partial agonist, dopamine transporter inhibitor, obesity model, anorectic
activity, excessive eating model
INTRODUCTION
The distribution of serotonergic 5-HT6 receptors within the central nervous system includes
hypothalamic regions, which play important role in appetite, food intake, and body weight control
(Heal et al., 2008). Studies indicated that 5-HT6 receptor ligands might have anti-obesity activity
(Woolley et al., 2001; Heal et al., 2008; Karila et al., 2015). The 5-HT6 receptor antagonists (i.e.,
PRX-07034, Ro 04-6790, BVT 5182, SB 271046) decreased food intake by enhancing satiety and
caused profound weight-loss in various rodent models of obesity (Heal et al., 2008; Karila et al.,
2015). Interestingly, Fisas et al. (2006) demonstrated anti-obesity effect of E-6837—a partial 5-HT6
receptor agonist. The compound caused significant hypophagia in non-obese and diet-induced
obese rats (Fisas et al., 2006; Heal et al., 2008).
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Dopamine transporter remains a potential target for
antagonist or antagonist-like substitution therapies for stimulant
abuse as well as obesity (Schmitt and Reith, 2010; Reith et al.,
2015). Dopamine receptor agonists reduce elevated levels
of the orexigenic neuropeptide and neuropeptide Y in the
hypothalamus and normalize the hyperphagia, body weight gain,
and hyperglycemia observed in obese ob/ob mice (Bina and
Cincotta, 2000). Increased extracellular dopamine levels (caused
by dopamine transporter inhibition) partially account for the
hypophagic and thermogenic effects of bupropion—a dopamine
and noradrenaline transporters inhibitor. Moreover, Liu et al.
(2004) proved that D1/D2 receptor blockade significantly
attenuated bupropion-induced thermogenesis.
Increased levels of dopamine might influence blood pressure
(Volkow et al., 2003) and visceral illness (Takeda et al.,
1993). Hypertension is often observed in patients treated with
dopamine and noradrenaline inhibitors, such as bupropion
(Cunningham and Wiviott, 2014) and tesofenasine (Appel
et al., 2014). Moreover, common side effects associated with
naltrexone/bupropion include nausea, vomiting (Makowski et al.,
2011).
EMD386088 was first presented by Mattsson et al. (2005)
as a 5-HT6 receptor agonist (EC50 = 1.0 nM) displaying
selectivity over other 5-HT receptors except for 5-HT3. It
also had no affinity for α1, α2, β1, D2, D3, GABAA, opioid
µ receptors, and 5-HT transporter (Jastrzebska-Wiesek et al.,
2013). Despite moderate affinity, EMD386088 acted neither
as agonist nor antagonist of serotonin 5-HT3 receptor in
biofunctional studies (Jastrzebska-Wiesek et al., 2014). Recent in
vitro studies demonstrated that EMD386088 behaved as a potent
5-HT6 receptor partial agonist (Jastrzebska-Wiesek et al., 2013).
EMD386088 also significantly blocked dopamine transporter
(Jastrzebska-Wiesek et al., 2016).
The interesting pharmacological profile of EMD386088
indicates that such type of compound might be beneficial in
the treatment of obesity. Therefore, in the present study we
aimed to evaluate the influence of EMD386088 on body weight,
food intake, and metabolic disturbances in high-fat diet-induced
obesity model and a model of excessive eating in rats. We also
determined the potential of the compound to induce emesis and
its influence on blood pressure.
MATERIALS AND METHODS
Animals
The experiments were carried out on male Wistar rats. Initial
body weight was: 140–160 g: obesity model, 190–220 g: model
of excessive eating, or 190–220 g: rats in which the models of
obesity or excessive eating were not induced. The animals were
housed in pairs in plastic cages in constant temperature facilities
exposed to a light-dark cycle; water and food were available ad
libitum. Control and experimental groups consisted of six to
eight animals each. All experiments were conducted according
to the guidelines of the Animal Use and Care Committee of
the Jagiellonian University and were approved for realization
(2013 and 2015, Poland; Permissions No. 136/2013 and
258/2015).
Drugs and Compounds
Heparin was delivered by Polfa Warszawa S.A. (Warsaw,
Poland), while thiopental sodium and ketoprofen were from
Sandoz GmbH (Austria), kethamine and xylasine from Biowet
Puławy (Poland), and cefuroxime from Polfarma S.A. (Poland).
EMD 386088 (Figure 1) was synthesized in the Department of
Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian
UniversityMedical College, Kraków, Poland.We chose two doses
of EMD 386088 (i.e., 2.5 and 5 mg/kg) based on our previous
experiments (Jastrzebska-Wiesek et al., 2016).
Obesity Induced with a High-Fat Diet and
Influence on Body Weight
Male Wistar rats were pair-housed and fed high-fat diet
consisting of 40% fat blend (Labofeed B with 40% lard,Morawski,
Manufacturer Feed, Poland) for 14 weeks, with water available
ad libitum (Dudek et al., 2015, 2016). Control rats were fed
a standard diet (Labofeed B, Morawski Manufacturer Feed,
Poland). After 10 weeks, rats with obesity induced via their
diet were randomly divided into three equal groups that had
the same mean body weight and were treated intraperitoneally
with test compounds at the following doses: 2.5 or 5 mg/kg
b.w./day and control group: vehicle—water 0.3 ml/kg (hight-
fat diet + vehicle = obesity control group) once per day in
the morning between 9:00 a.m. and 10:00 a.m. for 21 days.
Control rats were maintained on a standard diet throughout
21 days, with intraperitoneal administration of vehicle—water
(standard diet + vehicle = control group). Intakes of food and
water were measured three times per week, immediately prior
to administration of drugs. Animals always had free access to
feed and water. On the 22nd day, 20 min after intraperitoneal
administration of heparin 1000 j/rat and thiopental (70 mg/kg
b.w.) plasma was collected from animals.
High-fat feed composition (932 g of drymass): protein—193 g,
fat (lard)—408 g, fiber—28.1 g, crude ash—43.6 g, calcium—
9.43 g, phosphorus—5.99 g, sodium—1.76 g, sugar—76 g,
magnesium—1.72 g, potassium—7.62 g, manganese—48.7mg,
iodine—0.216mg, copper—10.8mg, iron—125mg, zinc—
61.3mg, cobalt—0.253 mg, selenium—0.304mg, vitamin
A—15000 units, vitamin D3—1000 units, vitamin E—95.3mg,
vitamin K3—3.0mg, vitamin B1—8.06mg, vitamin B2—6.47mg,
FIGURE 1 | Chemical structure of the test compound: EMD 386088.
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vitamin B6—10.3mg, vitamin B12—0.051mg, folic acid—
2.05mg, nicotinic acid—73.8mg, pantothenic acid—19.4mg,
choline—1578mg.
Hight-fat diet contained 100 g feed—550 kcal.
The Effect of EMD 386088 on Body Weight
and Food and Water Intake by Non-obese
Rats Fed Palatable Diet (Model of
Excessive Eating)
In order to determine the anorectic activity of EMD 386088,
its effect on caloric and water intake in the model of excessive
eating was assessed. Male Wistar rats (190–220 g) were housed
in pair. Two groups of 6 rats were fed diets consisting of milk
chocolate with nuts, cheese, salted peanuts, and 7% condensed
milk and also had access to standard feed (Labofeed B, Morawski
Manufacturer Feed, Poland) and water ad libitum for 3 weeks.
Palatable control group (palatable diet+ vehicle) received vehicle
(water, intraperitoneally), while palatable test group (palatable
diet + EMD 386088) was injected (intraperitoneally) with EMD
386088 at the dose 5mg/kg b.w. dissolved in water. Intakes of
food and water were evaluated three times per week, and body
weights weremeasured daily immediately prior to administration
of drugs. On the 22th day, 20 min after intraperitoneal
administration of heparin 1000 j/rat and thiopental (70mg/kg
b.w.) plasma was collected from animals.
Palatable diet contained: 100 g peanuts—614 kcal; 100 ml
condensedmilk—131 kcal; 100 gmilk chocolate with hazelnuts—
195 kcal; 100 g cheese (Greek type)—270 kcal.
Standard diet contained 100 g feed—280 kcal.
The Effect of EMD 386088 on Body Weight
and Food and Water Intake by Non-Obese
Rats Fed Only with Standard Diet
Male Wistar rats (190–220 g) were housed in pair. Control
group (standard diet + vehicle) received vehicle (water,
intraperitoneally), while the test group (standard diet + EMD
386088) was injected (intraperitoneally) with EMD 386088 at the
dose 5mg/kg b.w. dissolved in water. Intakes of food and water
were evaluated three times per week, and body weights were
measured daily immediately prior to administration of drugs.
Influence of EMD 386088 on Glucose Level
in Plasma
To determine the glucose level in plasma, standard enzymatic,
and spectrophotometric tests (Biomaxima S.A. Lublin, Poland)
were used. The substrate was decomposed with enzymes
appropriate for the relevant product, which was converted
to a colored compound. Coloration was proportional to the
concentration. The absorbance was measured at a wavelength of
500 nm.
Influence of EMD 386088 on Glycerol Level
in Diet-Induced Obese Rats
To determine the glycerol level in the plasma, Glycerol
Colorimetric Assay Kits (Cayman, USA) were used.
Effects of EMD 386088 on Visceral Illness
via Measurement of Kaolin Intake (Pica
Behavior)
To exclude the possibility that the suppression of food intake
by EMD 386088 was caused by visceral illness, pica behavior
was evaluated after administration. Test duration was 5 days. In
addition to free access to feed, animals had free access to the white
kaolin. For the first few days the animals were accustomed to the
presence of kaolin in their cages. On the fourth day they were
intraperitoneally given EMD 386088 at 5mg/kg b.w. or a vehicle
(negative control group) or a solution of CuSO4 at a dose of 6
mg/kg b.w. (1/3 LD50; LD50 = 18 mg/kg for a rat at this route of
administration; positive control group). The amount of approved
food, water drunk and kaolin consumed was determined after
24 h. Also, the animals were weighed prior to administration of
the compound and after 24 h.
Determination of the Effect of EMD 386088
on Blood Pressure during 22-h Study in
Wistar Rats Residing in Natural Housing
Conditions—Telemetric Method
The blood pressure of rats treated with EMD 386088
was measured during a 22 h period after 5 mg/kg b.w.,
intraperitoneally treatment with a special telemetric
system—Stellar (TSE-Systems, Germany; Dudek et al., 2016).
Surgery: The operation was performed over 30 min under
sterile conditions. The rats were anesthetized with kethamine
and xylasine (intramuscular injection: 100 and 10mg/kg). Before
surgery and for 7 days after, animals were additionally treated
with cefuroxime (20mg/kg/day) via intramuscular injection and
ketoprofen (5mg/kg/day) via intraperitoneal injection. Blood
flow in the abdominal aorta was blocked temporarily and the
tip of a transmitter for measuring pressure was inserted. The
transmitter was sutured to the peritoneal cavity.
The rats were individually caged for 2 weeks to heal after
surgical cut. Then, the animals were placed in pairs in cages to
reduce their isolation stress. Blood pressure wasmeasured: before
intraperitoneal administration of the compounds—time 0 min
and 22 h thereafter.
Statistical Analysis
Statistical calculations were performed using GraphPad Prism 6
program. Results are given as arithmetic means with a standard
error of the mean. Statistical significance was calculated using
Student’s t-test (if two groups were compared), one-way ANOVA
with Dunnett’s multiple comparison test post-hoc (biochemical
experiments), two-way ANOVA with Bonferroni test post-hoc
(in vivo experiments). Differences were considered statistically
significant at: p ≤ 0.05.
RESULTS
Influence of the Test Compounds on Body
Weight and Caloric and Water Intakes of
Obese Rats
EMD 386088 administered intraperitoneally at a dose of 5mg/kg
b.w. to rats fed high-fat diet caused a significant decrease in
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body weight gain compared with the obese rats (obesity control
group). The results are shown in Figure 2A. There was no
significant effect in terms of reducing body weight, when the
tested compound was administered intraperitoneally at a dose
of 2.5mg/kg b.w. EMD 386088 administered intraperitoneally
at a dose of 5mg/kg b.w. reduced the amount of calories
consumed by the animals in the test group as compared to the
obesity control group (Figures 3A,B). EMD386088 administered
intraperitoneally at doses of 2.5 and 5mg/kg b.w. reduced the
water intake in the test group as compared to the obesity control
group (Figure 3C). Since the dose 2.5mg/kg was inactive in
reducing body weight and caloric intake, we used only 5 mg/kg
in the following experiments.
Effect of EMD 386088 on Body Weight and
Calorie and Water Intakes in Model of
Excessive Eating and in Rats Fed Standard
Diet
EMD 386088 administered intraperitoneally at a dose of 5 mg/kg
b.w. reduced the amount of calories consumed by the animals
in the test group as compared with the control group (EMD
386088 fed palatable diet and control fed palatable diet), starting
from the first week of the experiment. Results are shown in
Figures 3D,E. Similar differences were observed in calorie intake
in the group with access only to standard feed (EMD 386088 fed
standard diet and control fed standard diet). Results are shown in
Figures 3G,H.
Similar to calorie intake, animals fed palatable feed and treated
with EMD 386088 showed significantly less weight gain than
animals in the control group consuming a preferential feed
(Figure 2B). From the seventh day of the experiment there
was a statistically significant difference between the groups.
The difference in weight on the seven day amounted to 5.02%,
and on the twenty-first day to 16.09%. Most importantly, the
body weight of rats treated with EMD 386088 and having
access to preferential feed did not differ significantly from
the weight of control animals fed standard feed. No effects
on body weight were noted in animals treated with EMD
386088 and consuming standard feed. Results are shown in
Figure 2C.
There were no significant differences in terms of the intake of
water by animals in groups fed preferential feed and groups fed
standard feed. Results are shown in Figures 3F,I.
Influence of EMD 386088 on Plasma
Glucose and Glycerol Levels in
Diet-Induced Obese Rats
In animals treated intraperitoneally with the tested compound
at a dose of 5 mg/kg b.w., significantly lower blood glucose was
observed as compared with a group of obese animals treated with
water. Results are showed in Figure 4A. EMD 386088, at a dose
of 5 mg/kg b.w., significantly increased plasma glycerol levels in
rats fed a high-fat diet, in comparison with the level of glycerol in
the obese control group (Figure 4B).
FIGURE 2 | Effect of long-term administration of EMD 386088 on body
weight in male Wistar rats. (A) The change in body weight in control
(standard diet) and diet-induced obese Wistar rats, and diet-induced obese
Wistar rats treated for 21 days with the tested compound; (B) The change in
body weight in Wistar rats fed palatable diet and in Wistar rats fed palatable
diet treated for 21 days with the tested compound; (C) The change in body
weight in control (standard diet) and in Wistar rats fed standard diet treated for
21 days with the tested compound. Results are means ± SEM, n = 6. Multiple
comparisons were performed by two-way ANOVA, Benferroni post-hoc. *p <
0.05, **p < 0.01, ***p < 0.001 significant vs. control rats fed standard diet; ∧p
< 0.05, ∧∧p < 0.01, ∧∧∧p < 0.001 significant vs. control rats fed fat diet
(diet-induced obesity control group); #p < 0.05, ##p < 0.01, ###p <
0.001 significant vs. control rats fed palatable diet.
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FIGURE 3 | Effect of long-term administration of EMD 386088 on food intake and water in male Wistar rats in weeks 1–3 and throughout the
experiment. (A) Obesity model—food intake in weeks 1–3; (B) Obesity model—food intake throughout the experiment; (C) Obesity model—water intake throughout
the experiment; (D) Excessive eating model—food intake in weeks 1–3; (E) Excessive eating model—food intake throughout the experiment; (F) Excessive eating
(Continued)
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FIGURE 3 | Continued
model—water intake throughout the experiment; (G) Standard diet fed Wistar rats—food intake in weeks 1–3; (H) Standard diet fed Wistar rats—food intake
throughout the experiment; (I) Standard diet fed Wistar rats—water intake throughout the experiment. Results are means ± SEM, n = 4, data for two animals housed
together. Multiple comparisons were performed by one-way ANOVA, Dunnett post-hoc, ∧p < 0.05, ∧∧p < 0.01, ∧∧∧p < 0.001 significant vs. control rats fed fat diet
(diet-induced obesity control group); Comparison were performed by t-Student test, #p < 0.05 significant vs. control rats fed palatable diet; *p < 0.05 significant vs.
control rats fed standard diet.
FIGURE 4 | Effects of long-term administration of EMD 386088 on plasma glucose level in male Wistar rats in diet-induced obesity model (A) or
excessive eating model (C) and on plasma glycerol level in male Wistar rats in diet-induced obesity model (B) or excessive eating model (D). Results are means ±
SEM, n = 6. Concentrations in plasma: mg/dl. Comparisons vs. the vehicle-treated control group (*) or vs. the vehicle-treated obesity (∧) or excessive eating control
groups (#) were performed by Student’s t-test (if two groups were compared) or one-way ANOVA, Dunnett post-hoc. Significant differences are denoted by ***p <
0.001, ∧∧∧p < 0.001, #p < 0.05, ###p < 0.001.
Influence of EMD 386088 on Plasma
Glucose and Glycerol Levels in the Model
of Excessive Eating
Glucose level was significantly lower in the group treated with
the tested compound at a dose of 5 mg/kg b.w., compared with
the level determined in the plasma of the control group fed
palatable feed (Figure 4C). EMD 386088, at a dose of 5 mg/kg
b.w., significantly increased plasma glycerol levels in rats fed
palatable feed, in comparison with the level of glycerol in the
control group. The results are presented in Figure 4D.
Effects of EMD 386088 on Visceral Illness
via Measurement of Kaolin Intake (Pica
Behavior)
Animals that received EMD 386088 intraperitoneally at a dose of
5 mg/kg b.w. did not consume more kaolin compared with the
control group which received only vehicle. Also, a comparable
amount of feed and water was ingested. The second control
group, which was given CuSO4, had a significantly higher kaolin
intake and a significantly lower feed and water intake. Results are
shown in Figure 5.
Influence of EMD 386088 on Blood
Pressure—Telemetric Method
After single intraperitoneal administration of EMD 386088 at
a dose of 5 mg/kg b.w. to rats residing in natural housing
conditions, there was a significant rise in systolic and diastolic
pressure to the 5th and 8th h after administration, respectively,
compared with rats that received water. Figures 6A,B show the
results.
DISCUSSION
We found that EMD 386088—a partial 5-HT6 agonist
and dopamine transporter inhibitor—reduced body
weight and decreased calorie intake in obese rats and
in the rat model of excessive eating. In both models
EMD 386088 regulated plasma glucose and increased
plasma glycerol levels. The compound did not cause
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emesis after single administration, but it increased blood
pressure.
Mattsson et al. (2005) introduced EMD 386088 as selective
(except for 5-HT3), high-affinity 5-HT6 receptor agonist.
However, our previous studies proved that the compound
behaved as partial 5-HT6 agonist (Jastrzebska-Wiesek et al.,
2013). Moreover, EMD386088 possessed significant affinity
for dopamine transporter (Jastrzebska-Wiesek et al., 2016).
Despite the affinity for serotonin 5-HT3 receptors, we showed
that EMD 386088 acted neither as agonist nor antagonist
in biofunctional studies (Jastrzebska-Wiesek et al., 2014).
In vivo experiments showed antidepressant- and anxiolytic-
like properties of the compound in rats (Jastrzebska-Wiesek
et al., 2014, 2015, 2016). Interestingly, Nikiforuk et al. (2011)
demonstrated that EMD 386088 ameliorated ketamine-induced
deficits relevant to schizophrenia in rats. Since 5-HT6 receptors
play role in controlling feeding and satiety (for review see
Voigt and Fink, 2015) and dopamine is essential for normal
feeding behavior (Billes and Cowley, 2007), we decided to
evaluate the ability of EMD 386088 to reduce body weight
in obese rats, as well as its anorectic properties (calorie
intake reduction) in rat model of excessive eating and the
influence on metabolism. Given the significant affinity of EMD
386088 for dopamine transporter, we also investigated pica
behavior in rats and the effect on blood pressure after single
administration.
Our results demonstrate that EMD 386088 at the dose
5mg/kg (but not 2.5mg/kg) significantly decreased body
weight in obese rats fed high fat diet compared with
vehicle-treated obese controls. Since 5-HT6 receptor ligands
influence satiety center, we evaluated if EMD 386088 reduced
palatable food consumption in normal rats (model of excessive
eating). The experiments revealed that rats treated with EMD
386088 (5 mg/kg) consumed less palatable food than vehicle-
treated controls. Moreover, we demonstrated that EMD 386088
administered to normal rats had no effect on body weight.
Weight disorders in animals with normal body weight could be
described as an unacceptable side effect, but this effect did not
occur. We also showed that EMD 386088 normalized plasma
glucose levels and increased plasma glycerol in both models
applied. The latter proves that the compound reduced body fat.
We think that it might have increased lipolysis but this issue
requires further studies. The reduction in glucose levels is the
first symptom of metabolic disorders compensation. Our results
are consistent with the results obtained by Fisas et al. (2006),
who demonstrated anti-obesity effect of E-6837—a partial 5-HT6
receptor agonist.
As mentioned earlier the data concerning the effect of 5-
HT6 receptor ligands is ambiguous. Nevertheless, according
to some authors 5-HT6 receptor antagonists reduce inhibitory
effects of GABA on pro-opiomelanocortin in the arcuate
nucleus neuron and consequently inhibit hunger signal induction
(Sargent and Henderson, 2011). Since similar to antagonists,
partial agonists reduce the response of full agonists (but to
a lesser extent), we think that this might be EMD 386088
mechanism of action. Moreover, studies demonstrated that
dopaminergic pathways play pivotal role in food consumption
FIGURE 5 | Effect of one administration of EMD 386088 on body weight
(A), food intake (B), kaolin intake (C), and water intake (D) in male Wistar rats
in the model of pica behavior. Results are means ± SEM, data for two animals
housed together, n = 6. Multiple comparisons against the vehicle-treated
control group (*) were by two-way ANOVA, Bonferroni post-hoc. Significant
differences are denoted by *p < 0.05, ***p < 0.001.
regulation (Baik, 2013). Scientists proved that compared with
non-obese controls obese patients showed reduced dopamine
D2 receptor availability or activity (Wang et al., 2001; Stice
et al., 2008; Volkow et al., 2008). Volkow et al. (2002)
showed that palatable food was associated with dopamine
release in healthy subjects. Conversely, in obese patients the
response to palatable food was reduced (Stice et al., 2010).
Altogether, the data proves that drugs rebalancing dopamine
system might be beneficial in the treatment of obesity.
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FIGURE 6 | Changes in the blood pressure after single administration
of EMD 386088 to normotensive rats (telemetric method). Changes in
systolic (A) and diastolic (B) blood pressure after single, intraperitoneal
administration of the test compound at a dose of 5 mg/kg b.w. to rats fed
standard diet. Mean ± SEM; n = 6 (two-way ANOVA, Bonferroni post-hoc).
*p < 0.05, **p < 0.01, ***p < 0.001 significant vs. control rats.
Accordingly, Appel et al. (2014) showed that tesofenasine,
a compound which inhibited, among others, dopamine re-
uptake, reduced body weight. Therefore, we think that dopamine
transporter inhibition contributes to EMD 386088 anti-obesity
effects.
5-HT3 receptor agonists may influence behavioral feeding,
have anorectic properties, and reduce body weight (Voigt and
Fink, 2015; e.g., SR-57227 Li et al., 2015). As mentioned
above, EMD 386088 had moderate affinity for serotonin 5-
HT3 receptor, but our biofunctional studies showed, that it
acted neither as agonist nor antagonist of serotonin 5-HT3
receptor (Jastrzebska-Wiesek et al., 2014). Therefore, we did
not consider the interaction with 5-HT3 receptor as potential
mechanism of anorectic and body-reducing action of EMD
386088.
Since EMD 386088 blocked dopamine transporter and
increased dopamine levels might cause emesis (D2 receptors
activation in the chemoreceptor trigger zone), we evaluated
pica behavior (kaolin intake) in rats. Pica behavior in rats is
analogous to vomiting in other species and is mediated by
the same mechanisms as in humans (Takeda et al., 1993). We
showed that single administration of the studied compound did
not influence kaolin intake in rats. Thus, we can exclude the
possibility that the suppression of food intake was due to visceral
illness.
Since the studied compound inhibited dopamine reuptake,
we determined the effect of single administration of EMD
386088 on blood pressure in rats (preliminary studies). The
compound increased systolic blood pressure for the first 5 h
and diastolic for 8 h after injection. After that time blood
pressure decreased to the baseline values. We think that this
temporal increase in blood pressure was due to dopamine
transporter inhibition and consequent increase in dopamine
level. Currently used anti-obese drugs, such as bupropion,
increase dopamine levels, and thus increase blood pressure
(Makowski et al., 2011; Cunningham and Wiviott, 2014). Body
weight reduction improves metabolic disorders and decreases
cardiovascular disease risk factor (Rosin, 2007; Soran et al.,
2016). The increase in blood pressure would be undesirable
in patients with essential hypertension and/or arrhythmias,
in whom cardiovascular disorders are not associated with
obesity. In these patients, dopamine transporter inhibitors
should be avoided or used very carefully under medical
supervision. We should emphasize that very often a tolerance
develops to the temporal increase in blood pressure after
catecholamine reuptake inhibitors (Makowski et al., 2011).
Moreover, body weight reduction and the metabolic disorders
improvement contributes to the reduction of hypertension
coexisting with obesity. Therefore, in case of the long-term use
of such drugs, the initial effect on blood pressure is not so
important.
The limitation of our study was that the blood pressure
was not evaluated throughout the experiment (for 21 days).
Therefore, in future studies we plan to confirm our findings
using other models of obesity (e.g., 30% fructose intake or
db/db mice) and simultaneously monitor blood pressure
and heart rate in animals (evaluation of cardiovascular
disease risk factor). Given the high affinity for dopamine
transporter, we also plan to evaluate the influence of EMD
386088 on locomotor activity of rodents after chronic
treatment.
CONCLUSIONS
In conclusion we demonstrated that EMD 386088—a partial
5-HT6 agonist and dopamine transporter inhibitor—reduced
body weight in obese rats and decreased calorie intake in
rat models of obesity and excessive eating. In both models
EMD 386088 regulated plasma glucose and increased plasma
glycerol levels. The compound did not cause pica behavior in
rats but increased blood pressure after single administration.
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We think that partial 5-HT6 agonists might have potential in
the treatment of obesity. Thus, EMD 386088 requires extended
studies.
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